National Cancer Institute (NCI): Multiple Myeloma trials
The registry lists 135 Multiple Myeloma studies with National Cancer Institute (NCI) as lead sponsor. 11 are open to participants now and 64 have results posted.
Phase 1 43Phase 2 85Phase 3 7No phase 12(a study in two phases counts in both)
Studies
Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaWithdrawnNCT01251172Phase 2
- Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure StudyCompletedNCT01139476
- Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)TerminatedNCT01109407
- Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood DisordersTerminatedNCT00973804Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaCompletedNCT00693433Phase 1
- Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy StudiesCompletedNCT00427726
- Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple MyelomaCompletedNCT00398515Phase 1
- Agriculture Health StudyActive, not recruitingNCT00352924
- Genome Expression in Lymphoma, Leukemia and Multiple MyelomaCompletedNCT00339963
- Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00310024Phase 1
- Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00253578Phase 2
- Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00243035Phase 1/2
- Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple MyelomaCompletedNCT00124605Phase 1
- Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
- Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple MyelomaCompletedNCT00088855Phase 2
- Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
- Temsirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00079456Phase 2
- FR901228 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00066638Phase 2
- Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
- Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
- Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
- Flavopiridol in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00047203Phase 2
- Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00033332Phase 3
- 2-Methoxyestradiol in Treating Patients With Advanced Solid TumorsCompletedNCT00028821Phase 1
- Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
- Vaccine Therapy in Treating Patients With Multiple MyelomaCompletedNCT00019097Phase 2
- Tipifarnib in Treating Patients With Advanced Hematologic CancerCompletedNCT00005967Phase 1
- 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00003853Phase 2
- Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
- Bryostatin and Vincristine in B-Cell MalignanciesCompletedNCT00003166Phase 1
- Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple MyelomaCompletedNCT00002556Phase 3
- Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow TransplantsCompletedNCT00001830Phase 1
- Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow TransplantationCompletedNCT00001561Phase 3